Immatics Publishes Presentation on IMA402 Phase 1b Results in Advanced Solid Tumors

• Immatics published an ESMO presentation on Phase 1b results for its PRAME-targeted bispecific T-cell engager IMA402 in advanced solid tumors.
• IMA402 with or without pembrolizumab achieved a 25% confirmed objective response rate among 40 patients at the June 1, 2026, cutoff.
• Confirmed responses reached 32% among 22 PRAME-high melanoma patients; median response duration was 12.5 months.
• The PRAME-high melanoma group recorded a 91% one-year overall survival rate; all patients had received prior immune checkpoint inhibitors.
• Grade 3 or higher treatment-related adverse events occurred in 52% of 126 patients; no IMA402-related deaths occurred.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.